Antibody-Drug Conjugates (ADCs) represent a revolutionary approach in cancer treatment by combining the selectivity of monoclonal antibodies with the potency of cytotoxic drugs. However, the unique complexity of ADCs — comprising an antibody, a linker, and a cytotoxic payload—introduces a range of analytical challenges.
This webinar explores these critical challenges, focusing on the characterization, stability, and potency of each ADC component. It highlights the need for comprehensive and customized analytical strategies to ensure the safety, efficacy, and consistency of these therapeutics. From ensuring antibody integrity and linker stability to accurately assessing payload potency and drug-to-antibody ratios, each step demands precision to navigate the intricate pathways of ADC development.
Join us for this insightful webinar as industry expert Christoph Lederer delves into cutting-edge analytical solutions that address these challenges, providing key strategies to optimize ADC development. Whether you're involved in drug discovery, process development, or quality control, this session will equip you with the knowledge to enhance your analytical approach. Don't miss this opportunity to stay ahead in next-generation cancer therapeutics—register now to secure your spot!
Key Learning Objectives
- Key analytical challenges in ADC development
- Advances and strategies in ADC technology
- CMC considerations: testing strategy details
